Begin typing your search above and press return to search.
DCGI Issues Notice To Glenmark Pharmaceuticals
By: Tupaki Desk | 20 July 2020 6:57 AM GMT
The Drugs Controller General of India (DCGI) has issued a notice to Glenmark Pharmaceuticals giant asking for clarification for its alleged false claims on the utilisation of anti-viral FabiFlu on coronavirus patients with comorbidities.
Drug Controller General of India, V.G. Somani has also asked for an explanation on the pricing of the drug.
Glenmark had priced FabiFlu, at Rs 103 per tablet during its launch, and an entire two-week course requires 122 tablets, which costs a total of Rs 12,500.
In a letter, Dr VG Somani has written to Glenmark directing them to give a clarification after his office received a representation from a MP.
The MP said in his letter, "The total cost of the treatment with FabiFlu will be around Rs 12,500 and that the cost proposed by Glenmark is definitely not in the interest of the poor, lower middle class and middle class people of India."
Drug Controller General of India, V.G. Somani has also asked for an explanation on the pricing of the drug.
Glenmark had priced FabiFlu, at Rs 103 per tablet during its launch, and an entire two-week course requires 122 tablets, which costs a total of Rs 12,500.
In a letter, Dr VG Somani has written to Glenmark directing them to give a clarification after his office received a representation from a MP.
The MP said in his letter, "The total cost of the treatment with FabiFlu will be around Rs 12,500 and that the cost proposed by Glenmark is definitely not in the interest of the poor, lower middle class and middle class people of India."
